This article reviews how glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as liraglutide, semaglutide, and tirzepatide are being used to treat obesity and related conditions, with a focus on gynecologic oncology. Originally for type 2 diabetes, these drugs have gained attention for potent weight loss, cardiovascular risk reduction, and improved glycemic control. Over 40% of U.S. adults were obese in 2020, with obesity linked to higher cancer risk and mortality—especially gynecologic cancers. Endometrial cancer risk rises 50% for every 5 kg/m² increase in BMI, and obesity worsens survival.
Apply for Free Samples
Apply for Free Samples
What the Research Shows
- GLP-1RAs now play a growing role in obesity management beyond diabetes.
- Benefits include weight loss, improved glycemic control, and reduced cardiovascular risk.
- Obesity is tied to cardiovascular disease, kidney dysfunction, sleep apnea, metabolic syndrome, and multiple cancers.
- Endometrial cancer risk ↑ 50% per 5 kg/m² BMI increase.
- Survival outcomes worsen with obesity.
- Barriers to weight loss: lifestyle change adherence, bariatric surgery risks.
- GLP-1RAs offer a noninvasive alternative with strong metabolic and weight outcomes.
- Health improvements: better insulin sensitivity, blood pressure, lipids, kidney function.
- May lower obesity-related cancer risk.
- Main side effects: gastrointestinal symptoms.
- In gynecologic oncology, obesity complicates surgery, chemotherapy dosing, and radiation.
- Pelvic floor benefits:
- Obesity raises risk for stress urinary incontinence, prolapse, fecal incontinence.
- Weight loss may reduce pelvic floor strain, improve urinary symptoms, and enhance post-surgical outcomes.
What This Means for Clinical Care
-
Consider GLP-1RAs for appropriate patients with obesity, including in cancer care.
-
Address obesity as a modifiable risk in prevention and survivorship.
-
Monitor for gastrointestinal side effects.
-
Include pelvic floor benefits in care planning.
-
Support pre- and post-treatment weight management in gynecologic oncology.
A Multidisciplinary Approach
-
Coordinate gynecologic oncology, obesity medicine, endocrinology, and pelvic floor specialists.
-
Pair GLP-1RAs with lifestyle interventions; assess bariatric surgery candidacy if relevant.
-
Educate patients on noninvasive options and sustained weight management.
-
Incorporate pelvic floor assessment and rehabilitation for optimal function and surgical outcomes.
- Zhihong Zhuo, Chuhan Wang, Huimin Yu, Jing Li, The Relationship Between Pelvic Floor Function and Sexual Function in Perimenopausal Women, Sexual Medicine, Volume 9, Issue 6, December 2021, Page 100441, https://doi.org/10.1016/j.esxm.2021.100441
When GLP-1s Come Up in Patient Care
Apply for Free Samples
